Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Kd in R/R Multiple Myeloma
NCT02899052Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Jan 2017; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02899052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899052.